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Background: Drug eluting stents have remarkably improved results of percutaneous coro-
nary angioplasty. Most of the currently available drug eluting stents uses a durable polymer
as drug carrier which has been implicated in local inflammatory response and continued
incidence of late and very late stent thrombosis. The Pronova XR stent is one from those
new generation polymer free sirolimus eluting stents in which pharmaceutical excipient is
used for the timed release of sirolimus from the XR stent platform instead of a polymeric
coating.
Methodology: We consecutively recruited 121 patients undergoing elective or urgent PCI at
our center. All the patients were followed up clinically and mandatory follow up angiogram
at 6 months was done for one third of the total patients. An independent core lab analyzed
paired angiograms.
Results: The primary efficacy endpoint was death, MI, TVR at 6 months which occurred in
6.66% patients. The QCA analysis showed reference vessel diameter of 2.5 þ 0.44 mm at
baseline and the minimal luminal diameter was 0.88 þ 0.43 mm giving baseline diameter
stenosis of 65.26 þ 15.89%. The immediate post procedure in-segment diameter stenosis
assessed was 23.68 þ 8.96% which increased to 36.02 þ 24.48% at follow up with a late
lumen loss of 0.25 þ 0.76 mm at mean of 191 days.
Conclusion: Coronary angioplasty with polymer free Pronova XR stents results in acceptable
late lumen loss and very low target lesion revascularisation at short and intermediate term
in unselected patients.
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polymers as drug carriers or being completely polymer free
(PF) DES.5
The Pronova XR stent is one from those new generation PF
sirolimus eluting stents (SES), in which a pharmaceutical
excipient is used for the timed release of sirolimus from the
XR stent platform instead of a polymeric coating. Release of
drug is maintained uniformly up to 30 days. After this time
less than 25% of the drug remains on the surface of the stent.
The aim of the present study was to evaluate safety and effi-
cacy of the novel stent system in consecutive patients with
denovo coronary lesions in a single center, prospective real
world study.1. Methods
The study was conducted between December 2008 and
September 2009 at Spandan Heart Institute and Research
Center, Nagpur. Patients undergoing elective or urgent PTCA
were enrolled consecutively after obtaining informed consent.
The study was conducted in accordance with declaration of
Helsinki and the study protocol was approved by Local Ethical
Committee of Spandan Heart Institute.
We planned to include 120 patients for the study. Angio-
graphic follow up was planned for 1/3rd of the patients and
was defined by a random table at the time of initial PTCA. All
patients were followed up for 6 months for clinical outcomes.
The study included all patients older than 18 years undergoing
elective or urgent PTCA with following exclusions e patients
with acute ST elevation MI, Chronic total occlusion, other
medical illnesses with life expectancy less than 1 year, known
allergy to aspirin or clopidogrel, Pregnancy or lactation and
participation in another study. All other patients willing to
undergo Pronova XR stent implantation were included after
obtaining informed consent.2. Study procedures and medications
Coronary angioplasty was performed using femoral approach
and standard practice. Lesions were predilated using under-
sized balloons and study stent was deployed at 12 atm pres-
sure. Post dilatation of the stents was performed using non
compliant balloon for suboptimal deployment assessed visu-
ally. Procedural success was defined as successful delivery of
stent at the intended lesion with visual residual stenosis less
than 50%.
Patients who were on chronic oral aspirin and clopidogrel
therapy did not receive loading of the drugs. Antiplatelet
treatment naı¨ve patients received 300 mg of clopidogrel and
325 mg of aspirin at least 2 h before the procedure. Unfrac-
tionated heparin was used as anticoagulant, initial dose being
70 IU/kg and subsequent doses administered to keep ACT
above 250. Use of Gp IIb/IIIa inhibitors was left to the discre-
tion of the operator. Sheaths were pulled out between 4 and
6 h as soon as ACT declined below 150. Patients were advised
to continue aspirin (150 mg) indefinitely and clopidogrel
(75 mg BID) for at least 6 months.Follow up angiogram were performed in 1/3rd of the pa-
tients who were scheduled at the time of the index procedure.
All other patients were followed up clinically and catheterized
if clinically indicated. The paired angiograms were sent to the
QCA core lab where further analysis was done. QCA parame-
ters included reference vessel diameter, percent diameter
stenosis, minimal luminal diameter, and late lumen loss. Bi-
nary re-stenosis was defined as stenosis of >50% or greater of
the minimal luminal diameter in the target lesion.3. Data collection and core laboratory
analysis
All the data were submitted to the independent core labora-
tory which was blinded to the clinical data and procedural
information. Digitally recorded coronary angiograms at
baseline, immediate post procedure and 6 months were
analyzed by the core laboratory using automated edge detec-
tion technique. The contrast filled nontapered catheter tip
was used for calibration. All angiographic measurements of
the target lesion were obtained in the “in-stent” zone, within
5 mm proximal and distal margins to each stent edge, and
over the entire segment (“in-segment” zone). The predefined
QCA parameters were calculated using Sanders Data System
QCA plus software (Palo Alto, CA, USA).4. Study endpoints
The primary endpoint of the study was clinical outcome
(MACE) at the end of 6 months which included Myocardial
Infarction (Q or NonQ wave), Death, clinically indicated target
vessel revascularization and stent thrombosis (definite,
possible or probable). Angiographic in-stent and in segment
restenosis along with late lumen loss constituted secondary
endpoints.5. Statistical analysis
Continuous variables were presented as mean and standard
deviation. A probability <0.05 was considered to be statisti-
cally significant. For angiographic parameters one-sided
paired t-test or Wilcoxon signed-rank test (depending on
normality) was used, becausemeasurements were dependent
and direction of difference was known; only the significance
of observed differences was investigated.
The primary endpoint and all study endpoints were
analyzed on the per-treatment evaluable population. Patients
lost in follow up were not included in the denominator for
calculations of binary endpoints.6. Results
One hundred and twenty one patients undergoing elective or
urgent PTCA at our center were included in the study. The
patient populationwas predominantlymale (103males and 18
Females). And the mean age of the enrolled patients was
Fig. 1 e Vessels treated.
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36% were known diabetics. Additionally 15% patients were
detected to be diabetic during the hospitalization. Of the total
population 13% were smokers and 8.25% patients had family
history of premature coronary artery disease. The details of
angina status and LV ejection fraction are summarized in
Table 1.
Of the total population, 57% (69 patients) had single
vessel disease while double and triple vessel disease was
present in 38% (46 patients) and 4.9% (06 patients). Of these
96 patients underwent PTCA to single vessel only while
double vessel PTCA was performed on 24 patients (32.6%).
One patient underwent triple vessel stenting. A total of 147
lesions were treated with 147 stent implantations (1.22 þ 0.4
stents per patients). The average stent diameter was
2.75 þ 0.36 mm and average stent length was 22.9 þ 8 mm.
Sixty stents of the 147 stents implanted were >28 mm. The
device success rate was 100%. Details of the vessels stented
are shown in Fig. 1.
Six months clinical follow up was available in 119 of 121
patients. One patient died due to sudden cardiac death 2
weeks after PTCA and one was lost to follow up. Follow up
angiography was planned for 40 patients of whom 39 un-
derwent angiography at a mean of 191 days after the index
procedure. One asymptomatic patient declined follow up
angiogram. The core lab provided analysis of 42 lesions in 36
patients. Three angiograms could not be included in the final
analysis due to technical difficulties. The QCA analysis
showed reference vessel diameter of 2.5  0.44 mm at base-
line and the minimal luminal diameter was 0.88  0.43 mm
giving baseline diameter stenosis of 65.26  15.89%. The im-
mediate post procedure in-segment diameter stenosis
assessed was 23.68  8.96 which increased to 36.02  24.48 at
follow up with a late lumen loss of 0.25 þ 0.76 mm at mean of
191 days. Other details of QCA are provided in Table 2. The
binary restenosis rate according to QCA was 9.52% (4 lesions
42 analyzed).7. Major adverse events
Total 08 (6.66%) patients suffered major adverse events at the
end of 6months. One patientwho underwent bypass surgery 8
years ago with severe LV dysfunction suffered sudden cardiac
death 2 weeks after PTCA. Six patients underwent repeat
revascularization- one CABG and 5 repeat PTCA for focal
restenosis. Of these six patients who underwent repeatTable 1 e Angina status.
Recent MI 36.9% (n ¼ 44)
Thrombolyzed 30.6% (n ¼ 37)
Non-thrombolyzed 05.8% (n ¼ 07)
Acute coronary syndrome 28.1% (n ¼ 45)
H/o MI 09.1% (n ¼ 11)
H/o CABG 01.6% (n ¼ 02)
Chronic stable angina 26.4% (n ¼ 32)
LV ejection fraction 51.4 þ 6.8%
Patients with LVEF <45% 33.1% (n ¼ 40)revascularization, 3 were from planned angio follow up and 3
patients required symptom driven re angio and revasculari-
zation. In addition one patient developed subacute stent
thrombosis after he stopped all medications 6 weeks after
index PTCA. Overall 93.4% patientswere free of any events at 6
month follow up.
We continued to follow these patients and extended
follow up was available for 115 patients for 2 years (mean
21  4 months). Four additional events were recorded be-
tween 6 months to the last follow up. One additional patient
underwent PTCA after 9 months, one patient required CABG
after 13 months, one patient succumbed after 10 months
(cause could not be ascertained) and one patient developed
myocardial infarction in untreated vessel after 14 months.
Three additional patients haveing exertional angina, are
being managed medically. Thus the 2 year MACE rate in this
study was 10.08%.8. Discussion
This study aimed at establishing a preliminary safety and
efficacy of Pronova XR, a novel polymer free sirolimus eluting
stent. This was a prospective single center study of patients
with denovo lesions with mandatory angiographic follow up
in 1/3rd of the enrolled patients at 6 months. The primary
endpoint was MACE at 6 months which occurred in 6.66%
patients treated with Pronova XR stent. The angiographic re-
stenosis rate in mandatory follow up angiography group was
9.52% and the in-segment late lumen loss noted in these
patients was 0.0.25 0.76mm. Considering the fact that there
were very high number of diabetics and the average stent
length was of 22.9 þ 8 mm these results are in tune with the
published results of other contemporary DES.6 It is also
noteworthy that 60 stents out of total 147 stents were longer
than 28 mm and the average reference vessel diameter was
2.5  0.44 at baseline. The primary efficacy endpoint was
freedom from Death, MI and TVR at the end of 6 months
which occurred in 6.66% patients included in the study. The
observedMACE rate at 6months in our study is comparable to
LEADERS trial which reported the primary endpoint of death,
MI and TVR in 9% patients treated with Biolimus eluting stent
Table 2 e QCA parameters.
Proximal edge In-stent Distal edge In-segment
Reference vessel diameter (mm)
Baseline 2.5  0.44
After procedure 2.81  0.38 2.57  0.35 2.44  0.38
At FU 2.83  0.57 2.65  0.52 2.55  0.51
Minimal lumen diameter (mm)
Baseline 0.88 þ 0.43
After procedure 2.43  0.50 2.2  0.35 1.99  0.41 1.93  0.37
At FU 2.44  0.70 1.84  0.76 2.07  0.64 1.72  0.75
Acute Gain 1.29  0.48
Late lumen loss (mm)
At FU 0.01  0.53 0.36  0.73 0.1  0.58 0.25  0.76
Diameter stenosis (%DS)
Baseline 65.26  15.89
After procedure 13.75  10.53 14.09  9.27 18.36  11.39 23.68  8.96
At FU 14.23  15.79 31.76  24.02 19.26  19.76 36.02  24.48
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months in ours study showed MACE rate of 10.08%. These
observations are comparable to long term follow up in
Resolute All comers study7 which showed MACE rate of 11.1%
and 14.2% in EES and SES at the end of 1 year. Three year
follow up of ISAR-TEST 4 study which compared stents with
biodegradable polymer to that with durable polymers was
reported by Byrne et al.8 This long term follow up study
showed event rate of 20.1% and 20.9% respectively in patients
treated with biodegradable polymer DES and durable polymer
DES. Our follow up period was shorter (2 years), but shows
comparable results to that of ISAR-TEST 4 study. Real world
patients have been reported to have higher MACE as
compared to the patients included in randomized trials.
Cosgrave et al9 reported real world experience using pacli-
taxel eluting stents (PES) and sirolimus eluting stents (SES) in
patients with denovo lesions. One year follow up showed
MACE rate of 21.3% in PES and 21.1% in SES groups. This study
included patients with multi-vessel disease, left main dis-
ease, bifurcations and diffuse disease. Our population was
similar to this with exception of left main disease. Raber
et al10 compared long term outcomes using EES and SES and
reported MACE rate of 11.1% and 14.2% in EES and SES groups
at the end of 1 year. MACE rate of 10.08% in our study is
comparable to these results.
Late lumen loss is identified as a more robust outcome
measure than binary restenosis, especially for the smaller
stent studies as shown by Mauri et al.11 Late loss from 0.1 to
0.7 mm predicted incremental binary restenosis according to
the observations made by them using 22 clinical trials of
DES. The in-stent late lumen loss observed in the current
study (0.36 þ 0.73 mm) was numerically higher than the late
lumen loss observed with the durable polymer-based siroli-
mus eluting stents like Cypher, or for newer everolimus
eluting stents (Xience/Promus) in randomized trials; how-
ever it did not translate in increased TLR or clinical events.
ISAR-TEST 1 study12 of ChoiceDES reported LLL of
0.48 þ 61 mm, while the subsequent ISAR-TEST 213 reported
a lower LLL. Another study using hydroxyapatite-based
release of sirolimus from the VESTAsync system14 demon-
strated LLL of 0.36 þ 23 which is similar to the LLL observedby us in the current study. Late lumen loss observed in real
world patients for PES and SES was 0.52 þ 0.7 mm and
0.27 þ 0.75 mm in the study by Cosgrave et al.9 Late lumen
loss observed by us in the current study is superior to that
observed for PES by Cosgrave et al and similar to the late
lumen loss for SES.
Binary restenosis observed in our studywas 9.52%which is
numerically higher than the randomized trials of drug eluting
stents. However symptom driven TLR at 6 months was very
low occurring in only 4.16% patients (total 5 patients e 2 from
mandatory angio follow up and 3 others). TVR at the end of
extended follow up in our study occurred in 6.66% patients (8
of the 120 patients). Raber et al10 reported a TVR of 7.0% and
9.6% at median interval of 1.5 years of the index procedure in
EES and SES groups. TVR observed in our study is comparable
to EES group and superior to SES group of this study.9. Conclusions
Coronary angioplasty with the polymer free Pronova XR stent
results in acceptable LLL and very low TLR at short and in-
termediate term in unselected patients.10. Study limitations
This study was a single center experience using Pronova XR
stent with relatively small number of patients. Mandatory
follow up angio was performed for 1/3rd patients only. How-
ever these patients were scheduled for follow up angio at the
time of index angioplasty removing the selection bias for the
check angiogram. A multi center trial with larger number of
patients will be important to evaluate the stent further.Conflicts of interest
All authors have none to declare.
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